1. Details on derivatives instruments and unheeded foreign currency exposures

(i) The following derivative positions are open as at 31 March, 2016. These transactions have been undertaken to act as economic hedges for the Company's exposures to various risks in foreign exchange markets and interest rate and have not been designated as hedging instruments.

Interest rate swaps to hedge against fluctuations in interest rate changes: As at 31 March, 2016 Rs, NIL (As at 31 March, 2015: Rs, 3.52 crores )

(ii) The Company uses foreign currency forward contracts to hedge its risks associated with foreign currency fluctuations. The use of foreign currency forward contracts is governed by the Company's strategy approved by the Board of Directors, which provide principles on the use of such forward contracts consistent with the Company's Risk Management Policy. The Company does not use forward contracts for speculative purposes. Outstanding short-term forward exchange contracts entered into by the Company on account of Receivable including forecast receivable:

2. Segmental Reporting

As the Company's annual report contains both Consolidated and Standalone Financial Statements, segmental information is _presented only on the basis of Consolidated Financial Statement. (Refer note 26.12 of Consolidated Financial Statements).

3. Employee benefit plans a) Defined Benefit Plans

i) Actuarial gains and losses in respect of defined benefit plans are recognized in the Statement of Profit & Loss.

ii) The Company has an obligation towards gratuity, a defined benefit obligation. The company makes lump sum payment to vested employees an amount based on 15 days last drawn basic salary including dearness allowance(if any) for each completed year of service or part thereof in excess of six months. Vesting occures upon completion of five years of service.

i. The Discount rate is based on the prevailing market yields of Indian Government securities as at the Balance Sheet date for the estimated terms of the obligations.

ii. Expected Rate of Return of Plan Assets: This is based on the expectation of the average long-term rate of return expected on investments of the Fund during the estimated term of obligations.

iii. Salary Escalation Rate: The estimates of future salary increases considered takes into account the inflation, seniority, promotion and other relevant factors.

Notes: Amount recognized as an expense in the Statement of Profit and Loss and included in note no. 24 under Salary and Wages are gratuity Rs, 1.54 crores (Previous Year Rs, 2.30 crores) and leave encashment Rs, (0.59) crores (Previous Year Rs, 0.98 crores).

4. Related party Disclousre

As per Accounting Standard 18, the disclosure of transactions with the related parties are given below: a) Details of related parties:

Description of relationship Name of the related party

Subsidiary Dishman USA Inc.

Subsidiary Dishman Europe Ltd.

Subsidiary Dishman International Trading (Shanghai) Co. Ltd.

Subsidiary Dishman Switzerland Ltd.

Subsidiary CARBOGEN AMCIS (Shanghai) Co. Ltd. [formerly known as

Dishman Pharmaceuticals & Chemicals (Shanghai) Co. Ltd.]

Subsidiary Dishman Pharma Solutions AG

Subsidiary Dishman Australasia Pty Ltd.

Subsidiary CARBOGEN AMCIS Ltd., U.K.

Subsidiary Carbogen Amcis (India) Ltd.

Subsidiary Dishman Care Ltd.

Subsidiary Dishman Middle East FZE

Subsidiary Dishman Japan Ltd. (w.e.f. to 10-12-2014)

Subsidiary Schutz Dishman Biotech Ltd. (w.e.f. 31-03-2016)

Step Down Subsidiary CARBOGEN AMCIS AG

Step Down Subsidiary Cohecie Fine Chemicals B.V.

Step Down Subsidiary Dishman Netherlands B.V.

Step Down Subsidiary Innovative Ozone Service Inc.

Step Down Subsidiary CARBOGEN AMCIS SAS

Step Down Subsidiary Shanghai Yiqian International Trade Co. Ltd.

Associates Bhadra Raj Holding Pvt. Ltd.

Joint Venture Schutz Dishman Biotech Ltd. (upto 30-03-2016)

Joint Venture Dishman Arebia Ltd. (Liquidated w.e.f. 05-01-2015)

Joint Venture Dishman Japan Ltd. (up to 09-12-2014)

Key Management Personnel (KMP) Mr. Janmejay R.Vyas

Key Management Personnel (KMP) Mrs. Deohooti J.Vyas

Key Management Personnel (KMP) Mr. Arpit J.Vyas

Relative of Key Management Personnel Ms. Aditi J Vyas

Relative of Key Management Personnel Ms. Mansi J Vyas

Entity in which KMP can exercise significant influence* B. R. Laboratories Ltd.

Entity in which KMP can exercise significant influence* Azafran Innovacion Ltd.

Entity in which KMP can exercise significant influence* Dishman Infrastructure Ltd.

Entity in which Relatives of KMP can exercise significant influence* Discus IT Pvt. Ltd.

* Only where transactions have taken place during the year.

5. During the year, Mr. Tushar D. Shah, Company Secretary has resigned w.e.f. 26th February, 2016 and Company is in process of appointing befitting candidate as Company Secretary. As per the provisions of Section 203 of Companies Act, 2013, the Company is required to fill-up such vacancy within a period of six months from the date of such vacancy.

6. The Board of Directors of the Company at their meeting held on 24th February, 2016 approved a Scheme of Arrangement and Amalgamation amongst the Company with its subsidiaries Dishman Care Limited and Carbogen Amcis (lndia) Limited. The Company has received Observation letter without any adverse comments from both Stock Exchanges i.e. National Stock Exchange of lndia Ltd., and Bombay Stock Exchange Ltd., and Company is in process of filing Draft Scheme with Honorable High Court of Gujarat.

7. Subsequent to 31st March, 2016, the Company has issued and allotted 80,697,136 equity shares of Rs,2/- each, as fully paid up bonus shares in the ratio of 1 (one) equity share for every 1 (one) Equity share held to those shareholders whose names appear in lhe Register of Members / List of Beneficial owners as on the Record Date i.e. on 3rd May,2016.

8. The Company has acquired further 50% stake in Schutz Dishman Biotech Ltd., a Joint Venture Indian Company, from the existing JV Partner i.e. SCHUTZ & CO. BETEILIGUNGSGESELLSCHAFT GMBH, Germany. Hence, with a stake of 72.33% Schutz Dishman Biotech Ltd., becomes a subsidiary of the Company.

9. Figures for the previous year have been regrouped/reclassified/rearranged wherever necessary to make them comparable to those for the current year.

Excluding Directorship in DPCL.

@ Directorship in Companies including overseas companies (listed, unlisted and private limited companies), including DPCL and its subsidiaries.

# As required by Regulation 26 of SEBI (LODR) Regulations, 2015, the disclosure includes chairpersonship and membership of the audit committee and the Stakeholders' Relationship Committee in Indian public companies (listed and unlisted)